JP2005500052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500052A5 JP2005500052A5 JP2003517223A JP2003517223A JP2005500052A5 JP 2005500052 A5 JP2005500052 A5 JP 2005500052A5 JP 2003517223 A JP2003517223 A JP 2003517223A JP 2003517223 A JP2003517223 A JP 2003517223A JP 2005500052 A5 JP2005500052 A5 JP 2005500052A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleic acid
- aaa
- aag
- fusion polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004927 fusion Effects 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 23
- 230000027455 binding Effects 0.000 claims description 16
- 239000005557 antagonist Substances 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 7
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims description 6
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 108060006698 EGF receptor Proteins 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 92
- 229920001184 polypeptide Polymers 0.000 claims 88
- 102000004196 processed proteins & peptides Human genes 0.000 claims 88
- 150000007523 nucleic acids Chemical class 0.000 claims 41
- 108020004707 nucleic acids Proteins 0.000 claims 29
- 102000039446 nucleic acids Human genes 0.000 claims 29
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 20
- 229960002897 heparin Drugs 0.000 claims 20
- 229920000669 heparin Polymers 0.000 claims 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 16
- 239000003446 ligand Substances 0.000 claims 14
- 229920002971 Heparan sulfate Polymers 0.000 claims 13
- 102000005962 receptors Human genes 0.000 claims 13
- 108020003175 receptors Proteins 0.000 claims 13
- 230000008685 targeting Effects 0.000 claims 7
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 6
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 210000004962 mammalian cell Anatomy 0.000 claims 6
- 238000000159 protein binding assay Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 241000282326 Felis catus Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 102000014413 Neuregulin Human genes 0.000 claims 4
- 108050003475 Neuregulin Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims 3
- 102400001368 Epidermal growth factor Human genes 0.000 claims 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 3
- 108090000054 Syndecan-2 Proteins 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 239000004020 conductor Substances 0.000 claims 3
- 229940116977 epidermal growth factor Drugs 0.000 claims 3
- 239000003900 neurotrophic factor Substances 0.000 claims 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 3
- JVJUWEFOGFCHKR-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(3,4-dimethylphenyl)cyclopentane-1-carboxylate;hydrochloride Chemical compound Cl.C=1C=C(C)C(C)=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 JVJUWEFOGFCHKR-UHFFFAOYSA-N 0.000 claims 2
- 102000002110 C2 domains Human genes 0.000 claims 2
- 108050009459 C2 domains Proteins 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 102000010803 Netrins Human genes 0.000 claims 2
- 108010063605 Netrins Proteins 0.000 claims 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 108060002566 ephrin Proteins 0.000 claims 2
- 102000012803 ephrin Human genes 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000472 traumatic effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 1
- 102000004230 Neurotrophin 3 Human genes 0.000 claims 1
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 1
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 229940032018 neurotrophin 3 Drugs 0.000 claims 1
- 229940097998 neurotrophin 4 Drugs 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30856301P | 2001-07-31 | 2001-07-31 | |
| PCT/US2002/024053 WO2003012045A2 (en) | 2001-07-31 | 2002-07-31 | Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005500052A JP2005500052A (ja) | 2005-01-06 |
| JP2005500052A5 true JP2005500052A5 (enExample) | 2006-06-15 |
| JP4314113B2 JP4314113B2 (ja) | 2009-08-12 |
Family
ID=23194471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003517223A Expired - Fee Related JP4314113B2 (ja) | 2001-07-31 | 2002-07-31 | ヘパラン硫酸プロテオグリカンに対する標的化のための、ニューレグリンヘパリン結合ドメインとのハイブリッドタンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7527794B2 (enExample) |
| EP (1) | EP1456239B1 (enExample) |
| JP (1) | JP4314113B2 (enExample) |
| AT (1) | ATE427317T1 (enExample) |
| AU (1) | AU2002322762B2 (enExample) |
| CA (1) | CA2455830C (enExample) |
| DE (1) | DE60231833D1 (enExample) |
| WO (1) | WO2003012045A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005271902B2 (en) * | 2004-07-09 | 2011-12-08 | Wayne State University | Hybrid proteins with erbB4 extracellular domain and neuregulin heparin-binding domain for targeting |
| US20110034383A1 (en) * | 2007-10-15 | 2011-02-10 | Institut Pasteur | Cxcl12 gamma a chemokine and uses thereof |
| EP2346526A2 (en) * | 2008-09-22 | 2011-07-27 | Massachusetts Institute of Technology | Compositions of and methods of using ligand dimers |
| WO2011119836A1 (en) | 2010-03-24 | 2011-09-29 | Massachusetts Institute Of Technology | Methods and compositions for cardioprotection and cardioregeneration |
| WO2011147981A2 (en) * | 2010-05-28 | 2011-12-01 | Mind-Nrg Sa | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
| US8961981B2 (en) | 2011-06-20 | 2015-02-24 | Saint Louis University | Targeting the neuromuscular junction for treatment |
| US20130058871A1 (en) * | 2011-07-28 | 2013-03-07 | Howard Hughes Medical Institute | Method and system for mapping synaptic connectivity using light microscopy |
| US9421245B2 (en) | 2012-06-25 | 2016-08-23 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| US20170333529A1 (en) * | 2015-01-20 | 2017-11-23 | Universiteit Antwerpen | Neuregulin in the treatment of fibrotic disorders |
| CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| WO2020142587A1 (en) | 2019-01-03 | 2020-07-09 | The Board Of Trustees Of The University Of Illinois | Method and kit for treating a neurodegenerative disease |
| WO2021062298A1 (en) | 2019-09-27 | 2021-04-01 | Arterez, Inc. | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8947791A (en) * | 1990-11-01 | 1992-05-26 | Scripps Research Institute, The | Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions |
| US5367060A (en) * | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
| WO1993022424A1 (en) * | 1992-04-29 | 1993-11-11 | Amgen Inc. | RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR |
| WO1994008007A1 (en) | 1992-09-29 | 1994-04-14 | President And Fellows Of Harvard College | Trophic factor having ion channel-inducing activity in neuronal cells |
| US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
| JP2000510879A (ja) | 1995-09-05 | 2000-08-22 | ケンブリッジ ニューロサイエンス，インコーポレイテッド | 特異的なオリゴ糖−ニューレグリン相互作用のためのアナログおよびその使用 |
| US6344436B1 (en) * | 1996-01-08 | 2002-02-05 | Baylor College Of Medicine | Lipophilic peptides for macromolecule delivery |
| ATE290595T1 (de) * | 1996-07-12 | 2005-03-15 | Genentech Inc | Gamma-heregulin |
| ATE486937T1 (de) | 1996-07-12 | 2010-11-15 | Genentech Inc | Chimärische heteromultimerische adhesine |
| KR100195886B1 (ko) | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
| WO1998043649A2 (en) | 1997-03-28 | 1998-10-08 | Otsuka Pharmaceutical Co., Ltd. | Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6? |
| AU4469997A (en) * | 1997-09-17 | 1999-04-05 | Urs Eppenberger | Heregulin-gamma |
| GB2363714B (en) | 1998-04-23 | 2004-03-03 | Vladimir Leko | Herbal composition and medicament against diabetes mellitus type II manufactured thereof |
| CA2325919C (en) * | 1999-01-29 | 2009-07-21 | Kaneka Corporation | Processes for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives |
-
2002
- 2002-07-31 DE DE60231833T patent/DE60231833D1/de not_active Expired - Lifetime
- 2002-07-31 AU AU2002322762A patent/AU2002322762B2/en not_active Ceased
- 2002-07-31 US US10/485,206 patent/US7527794B2/en not_active Expired - Lifetime
- 2002-07-31 JP JP2003517223A patent/JP4314113B2/ja not_active Expired - Fee Related
- 2002-07-31 WO PCT/US2002/024053 patent/WO2003012045A2/en not_active Ceased
- 2002-07-31 AT AT02756777T patent/ATE427317T1/de not_active IP Right Cessation
- 2002-07-31 CA CA2455830A patent/CA2455830C/en not_active Expired - Fee Related
- 2002-07-31 EP EP02756777A patent/EP1456239B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6350593B1 (en) | Receptors for fibroblast growth factors | |
| Tzahar et al. | Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network | |
| JP4723140B2 (ja) | 改善された薬物動態特性を有する改変キメラポリペプチド | |
| US7374757B2 (en) | Modified chimeric polypeptides with improved pharmacokinetic properties | |
| TWI454482B (zh) | 在活體中具有延長之半生期以及提高之紅血球生成活性的重組人類紅血球生成素（ｅｐｏ)-ｆｃ融合蛋白 | |
| US6184200B1 (en) | Truncated glial cell line-derived neurotrophic factor | |
| EP0805820A1 (en) | Ligands for eph-like receptors | |
| AU776393B2 (en) | Method of enhancing the biological activity of ligands | |
| CA2455830A1 (en) | Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans | |
| McDonald et al. | Expression and characterization of recombinant human ciliary neurotrophic factor from Escherichia coli | |
| AU2002322762A1 (en) | Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans | |
| HUE035554T2 (en) | VEGF antagonist compositions and their uses | |
| KR20080004480A (ko) | 티로신 키나제 억제제 조성물, 그의 제조 방법 및 이를이용한 질병 치료 방법 | |
| CN116964213A (zh) | 融合蛋白的制造方法 | |
| AU712737B2 (en) | Biologically active EPH family ligands | |
| CA2236001C (en) | Biologically active eph family ligands | |
| HK1132653B (en) | Modified chimeric polypeptides with improved pharmacokinetic properties | |
| HK1185798B (en) | Modified chimeric polypeptides with improved pharmacokinetic properties |